N	Concordance
1	have assessed an oral regimen combining idarubicin 30 mg/m2 and etoposide 80 mg/
2	by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italia
3	  associated with the administration of idarubicin and cladribine (2-chlorodeoxy
4	. Following chemotherapy treatment with idarubicin and cytarabine for seven days
5	phase I/II trial of escalating doses of Idarubicin (Ida) in conjunction with the
6	nst the  nonhematologic side effects of idarubicin (IDR) during induction therap
7	e cytarabine plus a single high dose of idarubicin in  patients with previously 
8	e induction chemotherapy  consisting of idarubicin IV over 5-15 minutes on days 
9	ive high dose cytarabine for 5 days and idarubicin on the third day as inductio
10	s. The development of the anthracycline idarubicin which is highly effective in